Home Cart Sign in  
Chemical Structure| 875-51-4 Chemical Structure| 875-51-4
Chemical Structure| 875-51-4

4-Bromo-2-nitroaniline

CAS No.: 875-51-4

4.5 *For Research Use Only !

Cat. No.: A255531 Purity: 98%

Change View

Size Price

USA Stock *0-1 Day

Global Stock *5-7 Days

In Stock
1g łÇʶÊÊ Inquiry Inquiry
5g łÇ˶ÊÊ Inquiry Inquiry
10g łÇÿ¶ÊÊ Inquiry Inquiry
25g łÇó¶ÊÊ Inquiry Inquiry
100g łËÿ¶ÊÊ Inquiry Inquiry
500g łî˶ÊÊ Inquiry Inquiry
1kg łÇó§¶ÊÊ Inquiry Inquiry

  • 1g

    łÇʶÊÊ

  • 5g

    łÇ˶ÊÊ

  • 10g

    łÇÿ¶ÊÊ

  • 25g

    łÇó¶ÊÊ

  • 100g

    łËÿ¶ÊÊ

  • 500g

    łî˶ÊÊ

  • 1kg

    łÇó§¶ÊÊ

In Stock

- +

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of [ 875-51-4 ]

CAS No. :875-51-4
Formula : C6H5BrN2O2
M.W : 217.02
SMILES Code : C1=C(Br)C=CC(=C1[N+](=O)[O-])N
MDL No. :MFCD00041312
InChI Key :ZCWBZRBJSPWUPG-UHFFFAOYSA-N
Pubchem ID :70132

Safety of [ 875-51-4 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H317-H319-H335
Precautionary Statements:P261-P280-P305+P351+P338

Calculated chemistry of [ 875-51-4 ] Show Less

Physicochemical Properties

Num. heavy atoms 11
Num. arom. heavy atoms 6
Fraction Csp3 0.0
Num. rotatable bonds 1
Num. H-bond acceptors 2.0
Num. H-bond donors 1.0
Molar Refractivity 47.37
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

71.84 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.35
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.9
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.95
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.05
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.33
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.18

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.72
Solubility 0.413 mg/ml ; 0.0019 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-3.03
Solubility 0.202 mg/ml ; 0.00093 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.28
Solubility 1.14 mg/ml ; 0.00527 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.27 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

3.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.25

Application In Synthesis [ 875-51-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 875-51-4 ]

[ 875-51-4 ] Synthesis Path-Downstream   1~10

  • 2
  • [ 875-51-4 ]
  • [ 20358-03-6 ]
  • 3
  • [ 875-51-4 ]
  • [ 181765-85-5 ]
  • [ 755026-37-0 ]
YieldReaction ConditionsOperation in experiment
89% With potassium carbonate;copper; In chlorobenzene; for 48h;Heating / reflux; A mixture of <strong>[181765-85-5]methyl 4-chloro-2-iodobenzoate</strong> (5.93g, 20 mmol), 4-bromo-2-nitroaniline (4.34g, 20 mmol), copper (1.26g, 20 mmol), and K2CO3 (2.76g, 20 mmol) in chlorobenzene (300 mL) was heated to reflux for 2 days, cooled to room temperature, diluted with ethyl acetate, and filtered through diatomaceous earth (CELITE#). The solution was washed with water and brine, dried (MGS04), filtered, and concentrated under vacuum. The residue was purified by flash column chromatography on silica gel with 9: 1 hexanes/ethyl acetate to provide 6.86g (89 %) of the desired product. MS (DCI) m/e 386 (M+H) +, 403 (M+NH4) + ; 1H NMR (300 MHz, DMSO- D6) 8 10.83 (s, 1H), 8.28 (d, J = 2.4 Hz, 1H), 7.97 (d, J = 8.5 Hz, 1H), 7.82 (dd, J = 9.1, 2.4 Hz, 1H), 7.63 (d, J = 9. 1 HZ, 1H), 7.52 (d, J = 2. 1 HZ, 1H), 7.17 (dd, J = 8. 5, 2 Hz, 1H), 3.87 (s, 3H).
  • 4
  • [ 875-51-4 ]
  • [ 707-07-3 ]
  • [ 1741-50-0 ]
  • [ 716-79-0 ]
YieldReaction ConditionsOperation in experiment
80% With indium; acetic acid; In ethyl acetate; for 1.5h;Reflux; Inert atmosphere; General procedure: 2-Nitroaniline derivative (1 mmol) was added to a mixture of indium powder (574 mg, 5.0 mmol for 2-nitroaniline, 918 mg 8.0 mmol for 1,2-dinitroarene), and acetic acid (0.572 mL, 10 mmol) in ethyl acetate (2 mL), followed by the addition of trimethyl orthoester (2.0 mmol) in ethyl acetate (3 mL for 2-nitroaniline; 8 mL for 1,2-dinitroarene). The reaction mixture was stirred at reflux under a nitrogen atmosphere. After the reaction was completed, the reaction mixture was diluted with ethyl acetate (30 mL), filtered through Celite, poured into 10% NaHCO3 (30 mL), and then extracted with ethyl acetate (30 mL×3). The combined organic extracts were dried over MgSO4, filtered, and concentrated. The residue was eluted with ethyl acetate/hexane (v/v=10/90) for 2-phenylbenzimidazole derivatives or methanol/dichloromethane (v/v=1/99) for 2-methylbenzimidazole derivatives through a silica gel column to give the corresponding benzimidazoles. The structures of the benzimidazoles were characterized by 1H NMR, 13C NMR, FTIR, and GC-MS, and were mostly known compounds. HRMS data were reported in addition for unknown compounds.
  • 5
  • [ 875-51-4 ]
  • [ 337915-79-4 ]
  • 6
  • [ 875-51-4 ]
  • [ 100-51-6 ]
  • [ 1741-50-0 ]
YieldReaction ConditionsOperation in experiment
81% With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; In toluene; at 160℃; for 24.0h;Schlenk technique; Inert atmosphere; Sealed tube; General procedure: GeneralProcedure for the preparation of 2-Phenyl-1H-benzoimidazole (3aa): A 25mL over-dried Schlenk tube was charged with 2-nitroaniline (41.4 mg, 0.3 mmol),benzyl alcohol (97.2 mg, 0.90 mmol) and Pd(dppf)Cl2 (12.2 mg, 0.015mmol). The tube was purged with nitrogen three times. Toluene (1 mL) was addedto the sealed reaction vessel by syringe. The reaction mixture was stirred in apreheated oil bath at 160 oC for 24 h. After cooling to roomtemperature, the reaction mixture was then concentrated in vacuo, and theresidue was purified by column chromatography (silica gel, petroleumether/ ethyl acetate = 4:1) to give 3aa as a pale yellow solid (56.5 mg, 97%).
73% With sodium sulfide hydrate; iron(III) chloride hexahydrate; at 140℃; for 24.0h;Inert atmosphere; General procedure: A 20-mL test-tube equipped with a magnetic stirring bar was charged with o-nitroaniline 1 (2.5 mmol, 1 equiv), alcohol 2 or 5 (3 mmol, 1.2equiv), Na2S·nH2O (≥60%, 130 mg, 1 mmol, 40 mol%) and FeCl3·6H2O(7 mg, 0.025 mmol, 1 mol%). The resulting mixture was stirred for 24h under an argon atmosphere at the indicated temperature (see Schemes 2 and 3 and Table 2). After cooling to r.t., the mixture was purified in different ways. (i) For NH benzimidazole products, the mixture was washed with CH2Cl2 (3 × 2 mL) then dissolved in MeOH.The MeOH solution was filtered through a short pad of silica gel. The filtrate was concentrated in vacuo to afford the NH benzimidazole product. Further purification by column or recrystallization was carried out if necessary. (ii) For N-methyl-2-phenylbenzimidazole 3ha and quinoxalines 5, the crude mixture was dissolved in a minimum volume of CH2Cl2 and purified by column chromatography (silica gel or alumina, heptane-EtOAc, EtOAc, EtOAc-MeOH, hexane-Et2O). We noted that some 13C NMR signals of NH-benzimidazoles are missing or difficult to observe.
73% With 1,1'-bis-(diphenylphosphino)ferrocene; In toluene; at 150℃; for 24.0h;Inert atmosphere; Sealed tube; General procedure: The preparation of 2-phenyl-1H-benzoimidazole (3a): A 15 mL capped tube was charged with 2-nitroaniline (0.36 mmol), benzyl alcohol (0.094 mL, 0.90 mmol) and dppf (0.018 mmol). The tube was flushed with argon for 10 min. Then the degassed toluene (3 mL) was added. The tube was flushed with argon, capped, and heated at 150 C for 24 h. After cooling to room temperature, the reaction mixture was then concentrated in vacuo, and the residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 4:1) to afford the pure 3a as a white solid. The product was identified by NMR and MS and the data are identical to the reported values.
  • 7
  • [ 875-51-4 ]
  • [ 16429-44-0 ]
  • 8
  • [ 1049730-42-8 ]
  • [ 875-51-4 ]
  • 2-nitro-4-[1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]aniline [ No CAS ]
YieldReaction ConditionsOperation in experiment
941 mg With bis-triphenylphosphine-palladium(II) chloride; potassium carbonate; triphenylphosphine; In propan-1-ol; for 2h;Reflux; To a stirred solution of 4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 -(2,2,2-trifluoroethyl)- 1H-pyrazole (1.76 g, 6.06 mmol) in 1-propanol (42 ml) was added potassium carbonatesolution (7.0 ml, 2.0 M, 14 mmol), 4-bromo-2-nitroaniline (1.01 g, 4.66 mmol), triphenylphosphine (61.1 mg, 233 pmol) and PdCI2(PPh3)2 (164 mg, 233 pmol). The mixture was heated to reflux for 2 h. Water was added and the mixture was extracted with ethyl acetate. The organic phase was dried (sodium sulfate), filtered and the solvent was removed in vacuum. Aminophase-silicagel chromatography gave 941 mg of the title compound.LC-MS (Method 2): R = 1.00 mm; MS (ESIpos): m/z = 287 [M+H]1H..NMR (400 MHz, DMSO-d6) [ppm]: 1.066 (0.59), 1.172 (0.65), 1.987 (1.19), 2.518 (2.95),2.523 (2.06), 5.090 (3.14), 5.113 (9.09), 5.136 (8.48), 5.159 (2.55), 7.045 (9.54), 7.067 (9.88),7.471 (12.23), 7.671 (5.50), 7.676 (5.37), 7.693 (4.69), 7.698 (5.06), 8.004 (15.43), 8.006(16.00), 8.132 (10.24), 8.137 (10.07), 8.253 (13.82).
  • 9
  • [ 881674-56-2 ]
  • [ 875-51-4 ]
  • 1-(4-bromo-2-nitrophenyl)-5-(2-fluorophenyl)-1H-pyrrole-3-carbaldehyde [ No CAS ]
YieldReaction ConditionsOperation in experiment
76% With potassium phosphate; copper; In dimethyl sulfoxide; at 90℃; for 16h; General procedure: A mixture of <strong>[881674-56-2]5-(2-fluorophenyl)-1H-pyrrole-3-carbaldehyde</strong> 1 (5.28 mmol), different o-fluoritro benzene 2 (6.33mmol), copper powder and K3PO4 (15.84 mmol) in anhydrous dimethyl sulfoxide (50ml) was heated to 90. After 16h, the reaction mixture was cooled to room temperature and filtered, the filtrate was poured into water and extracted with ethyl acetate. The combined organic extracts were washed with water, dried over anhydrous Na2SO4, filtered and evaporated in vacuo. The crude product was purified on the silica gel to afford 3a-d as yellow solids.
  • 10
  • [ 14547-73-0 ]
  • [ 875-51-4 ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 875-51-4 ]

Aryls

Chemical Structure| 59255-95-7

A203705 [59255-95-7]

2-Bromo-6-nitroaniline

Similarity: 0.94

Chemical Structure| 6311-60-0

A111519 [6311-60-0]

1,3-Dibromo-5-nitrobenzene

Similarity: 0.91

Chemical Structure| 55215-57-1

A680470 [55215-57-1]

3-Bromo-5-nitroaniline

Similarity: 0.91

Chemical Structure| 5411-50-7

A102042 [5411-50-7]

1,2-Dibromo-4-nitrobenzene

Similarity: 0.90

Chemical Structure| 84752-20-5

A102413 [84752-20-5]

5-Bromo-3-nitrobenzene-1,2-diamine

Similarity: 0.88

Bromides

Chemical Structure| 59255-95-7

A203705 [59255-95-7]

2-Bromo-6-nitroaniline

Similarity: 0.94

Chemical Structure| 6311-60-0

A111519 [6311-60-0]

1,3-Dibromo-5-nitrobenzene

Similarity: 0.91

Chemical Structure| 55215-57-1

A680470 [55215-57-1]

3-Bromo-5-nitroaniline

Similarity: 0.91

Chemical Structure| 5411-50-7

A102042 [5411-50-7]

1,2-Dibromo-4-nitrobenzene

Similarity: 0.90

Chemical Structure| 84752-20-5

A102413 [84752-20-5]

5-Bromo-3-nitrobenzene-1,2-diamine

Similarity: 0.88

Amines

Chemical Structure| 59255-95-7

A203705 [59255-95-7]

2-Bromo-6-nitroaniline

Similarity: 0.94

Chemical Structure| 55215-57-1

A680470 [55215-57-1]

3-Bromo-5-nitroaniline

Similarity: 0.91

Chemical Structure| 84752-20-5

A102413 [84752-20-5]

5-Bromo-3-nitrobenzene-1,2-diamine

Similarity: 0.88

Chemical Structure| 6311-47-3

A317490 [6311-47-3]

5-Bromo-2-nitro-N-phenylaniline

Similarity: 0.87

Chemical Structure| 5228-61-5

A556178 [5228-61-5]

5-Bromo-2-nitroaniline

Similarity: 0.86

Nitroes

Chemical Structure| 59255-95-7

A203705 [59255-95-7]

2-Bromo-6-nitroaniline

Similarity: 0.94

Chemical Structure| 6311-60-0

A111519 [6311-60-0]

1,3-Dibromo-5-nitrobenzene

Similarity: 0.91

Chemical Structure| 55215-57-1

A680470 [55215-57-1]

3-Bromo-5-nitroaniline

Similarity: 0.91

Chemical Structure| 5411-50-7

A102042 [5411-50-7]

1,2-Dibromo-4-nitrobenzene

Similarity: 0.90

Chemical Structure| 84752-20-5

A102413 [84752-20-5]

5-Bromo-3-nitrobenzene-1,2-diamine

Similarity: 0.88